Short-Term Debt to Capital: Co-Diagnostics Inc (CODX)

This price chart for Co-Diagnostics, Inc. (CODX) reflects the dynamics of a company dominating the PCR diagnostics segment, generating stable royalties through its patented Co-Primers developments. The current metric stands at 0.06. The business adheres to ESG and bioethics standards, strictly protecting client personal data. Biomaterial logistics have been outsourced to external partners, which ensures the resilience of operational processes through a system of redundant routing.

This indicator assesses the share of short-term liabilities within the equity structure, determining the degree of financial autonomy and liquidity risk for Co-Diagnostics, Inc. (CODX). By analyzing the shifting ratio of short-term loans to equity, an investor can gauge the dependence of Co-Diagnostics, Inc. (CODX) on external financing, which is critical during disruptions in Asian electronics supplies or the tightening of US export controls on biotechnology.